solid tumors

CARY, N.C. and BRADENTON, Fla., May 20, 2026 Continuity Biosciences has announced the initiation of a Phase I first-in-human...

CAMBRIDGE, UK, May 19, 2026 Mestag Therapeutics announced the first patient has been dosed in the Phase 1 STARLYS...

CHENGDU, China, May 12, 2026 Kelun-Biotech announced that China’s Center for Drug Evaluation (CDE) under the National Medical Products...

OSLO, Norway, May 6, 2026 Zelluna ASA announced the activation of the first clinical site for its ZIMA-101 Phase...

WATERTOWN, MASSACHUSETTS, April 28, 2026 Kestrel Therapeutics Inc. has announced a major clinical milestone with the first patient dosed...

Cambridge, Massachusetts, USA – April 23, 2026 Repertoire Immune Medicines announced a major clinical milestone with the first participant...

OXFORD, UK, April 20, 2026 Enara Bio announced the presentation of breakthrough preclinical data for ENA101, its first-in-class bispecific...

PHILADELPHIA, April 20, 2026 Verismo Therapeutics has reported promising initial Phase 1 clinical data from its STAR-101 trial, evaluating...

SHANGHAI, China, April 10, 2026 Oricell Therapeutics Holdings Limited has successfully closed a $110 million pre-IPO financing round, marking...

South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...